BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

Abstract excerpt

After more than a decade of clinical experience with Bruton tyrosine kinase (BTK) inhibitors, resistance to BTK targeting has become a moving target, shaped by drug-specific BTK mutations, downstream signaling escape, and disease-dependent adaptive programs. The arrival of BTK degraders introduces a mechanistically distinct modality for lymphoid malignancies but also raises a timely question: does degrading BTK...

Topics

• Humans
• Agammaglobulinaemia Tyrosine Kinase
• Drug Resistance, Neoplasm
• Protein Kinase Inhibitors
• Lymphoma
• Mutation
• Antineoplastic Agents